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Abstract
The expression of the gene encoding adrenomedullin (AM), a multifunctional peptide hormone, in the prostate is localized to the
epithelial cells. Prostate cancer cells are derived from prostatic epithelial cells. To elucidate the potential role of the AM gene in
prostate cancer progression, we have stably-transfected the PC3 human prostate cancer cell line with an AM gene expression vector.
The AM-transfected PC3 sublines were studied along with parental and empty vector transfected PC3 cells as controls. The average
level of AM in the conditioned media of AM-transfected cells was 0.9599/0.113 nM, a physiologically relevant concentration. The
ectopic expression of AM gene inhibited the proliferation of PC3 cells in culture dishes. In addition, anchorage-independent growth
of the transfected sublines was virtually abolished in soft agar assays. Flow cytometry studies showed that overexpression of AM
gene caused a very significant G1/G0 cell cycle arrest. In vivo experiments demonstrated that AM gene expression markedly inhibited
the growth of xenograft tumors in nude mice. Our in vivo and in vitro studies suggest that AM could strongly suppress the
malignancy of prostate cancer cells, via autocrine and/or paracrine mechanisms.
# 2002 Published by Elsevier Science Ireland Ltd.
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1. Introduction
Adrenomedullin (AM) is a pluripotent peptide origin-
ally isolated from human pheochromocytoma. The gene
for AM is located in a single locus of chromosome 11
and encodes a 185-a.a. preprohormone (Kitamura et al.,
1993b). The preproAM is enzymatically processed to
yield two C-terminal amidated bioactive peptides, AM
and pro-AM N-terminal 20 peptide (PAMP). AM
consists of 52-amino acids in human and 50 in rat,
whereas PAMP has only 20 amino-acid residues in both
species. Structurally, AM belongs to a peptide family
that includes calcitonin gene-related peptide (CGRP)
and amylin (Muff et al., 1995). Both rat (rAM) and
human AM (hAM) contain a disulfide cysteine-to-
cysteine bond forming a six-membered amino acid ring
structure. The amino acid sequence of AM peptide is
highly conserved evolutionarily.
The expression of AM has been detected in a variety
of mammalian cells and organs, both in normal and in
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malignant settings (Montuenga et al., 1998). Although
AM and PAMP are derived from the same precursor,
they are not always expressed in the same cell types. A
new splicing mechanism recently described may explain
the differential distribution of AM and PAMP among
organs and cell types (Martinez et al., 2001). Both AM
and PAMP are present in plasma (Kitamura et al.,
1994a; Washimine et al., 1994) and were initially
described for their hypotensive activity and their ability
to elevate cAMP (Kitamura et al., 1994b, 1993a). In the
last few years, many other functions have been attrib-
uted to these peptides, including bronchodilation (Ka-
nazawa et al., 1994), antibacterial action (Walsh et al.,
1996), and control of hormonal secretion (Martinez et
al., 1996). Furthermore, AM has been reported to act as
a cell growth regulator (Miller et al., 1998). It stimulates
the growth in some types of cells (Andreis et al., 2000;
Cornish et al., 1997; Kapas et al., 1997; Moody et al.,
2000; Udono et al., 2000), but suppresses cell growth in
others (Ando et al., 1997; Chini et al., 1995; Tsuruda et
al., 1999). AM and its receptors are expressed during
fetal development, in a variety of tumors, and in several
cancer cell lines, suggesting an autocrine/paracrine role
of this peptide in the control of growth and tumorigen-
esis (Martinez et al., 1997a,b; Miller et al., 1996;
Montuenga et al., 1997). On the other hand, PAMP
has been only reported to inhibit the proliferation of
human neuroblastoma cells (Ando et al., 1997).
Many of the biological actions of AM and PAMP are
mediated through G protein-coupled receptors (Iwasaki
et al., 1996; Kato et al., 1995; Kitamura et al., 1994a).
The activation of these receptors leads to the activation
of adenyl cyclase and protein kinase A (PKA). The
elevation of cAMP is a major step in the signal
transduction pathway activated by AM. AM can also
influence many other signaling steps such as calcium
signaling (Szokodi et al., 1998), cGMP (Ali et al., 2000),
K-ATP channels (Terata et al., 2000), c-fos gene
expression (Sato and Autelitano, 1995), and MAPK
(Iwasaki et al., 1998; Parameswaran et al., 1999).
Using a PCR-based cDNA subtraction method, we
have identified AM as an androgen-response gene on
the basis of its induction in the regressed rat ventral
prostate by androgen replacement (Wang et al., 1997).
Further studies showed that AM mRNA is localized to
the prostatic epithelium and the level of its expression is
directly and markedly regulated by androgen manipula-
tion (Pewitt et al., 1999). AM peptide has been also
detected in the human prostate epithelium (Jime´nez et
al., 1999). These observations suggest that the AM gene
may play an important role in the prostate and/or
prostate cancer progression.
In an attempt to address its role in the prostate, we
characterized the effect of ectopic expression of the AM
gene on PC3 cells. Since its isolation in 1977 by Kaighn
et al. (1979), PC3 cell line has been widely used as an in
vitro model of the androgen-independent prostate
cancer in humans. In this paper we report the effect of
the AM gene overexpression on anchorage-dependent
and -independent cell proliferation, tumorigenicity in
vivo, and cell cycle distribution in the PC3 model. The
results strongly suggest that AM could function as a
potent growth inhibitor of prostate cancer cells.
2. Materials and methods
2.1. Cell culture
PC3 cells were purchased from the American Type
Culture Collection (Rockville, MD). Cells were routi-
nely maintained in RPMI 1640 medium containing 10%
fetal bovine serum (FBS), penicillin (100 U/ml), strep-
tomycin (100 mg/ml) and 2 mM L-glutamine (all from
Gibco BRL, Rockville, MD). Cells were cultured in a
humidified incubator at 37 8C in the presence of 5%
CO2.
2.2. pcDNA3.1/Hygro expression vectors and
transfections
The full-length cDNA of the rAM gene was isolated
from a lZAP cDNA phage library constructed from
normal rat ventral prostate mRNA. The fragment was
cloned into pcDNA3.1/Hygro mammalian expression
vector (Invitrogen, Carlsbad, CA) at EcoRV and XbaI
sites. The insert of the plasmid was sequenced using
ALFexpress automated sequencing machine (Amer-
sham Biosciences, Piscataway, NJ). Stable transfection
experiments of the vector containing the AM gene and
the empty vector were carried out using LIPOFECTA-
MINETM according to the protocol provided by the
manufacturer (Gibco BRL, Rockville, MD). The cells
were diluted and placed under selection 24 h after
transfection with RPMI 1640 medium containing 150
mg/ml hygromycin B (Invitrogen, Carlsbad, CA). Several
individual clones were randomly chosen to study the
AM gene expression. Finally, three AM-transfected and
two empty vector-transfected PC3 sublines were tested
to reduce clonal variations.
2.3. RNA isolation and Northern blot analysis
Total RNA was isolated by guanidinium/CsCl gra-
dient method (Chirgwin et al., 1979). Purified RNA
samples were fractionated by electrophoresis through
1.4% formaldehyde/agarose gels, capillary transferred
overnight to nylon membrane (MAGNA, Micron
Separations Inc., Westborough, MA, USA) and then
cross-linked to the membrane by UV irradiation.
Labeled probes were prepared using random hexamer
oligonucleotide priming in the presence of a-32P-deox-
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ycytidine triphosphate. Full-length cDNA of approxi-
mately 1.4 kb was used as the template in the probe
labeling reaction. Northern blot hybridization was
performed overnight at 42 8C in a buffer containing
5/ SSPE, 2/ Denhardt’s solution, 0.1% SDS, 50 mg/
ml denatured salmon sperm DNA, and 50% formamide.
Blots were first washed once at 42 8C for 30 min, with
an excess of wash buffer consisting of 1/ SSC and 0.1%
SDS and then three times at 65 8C for 30 min, with
0.2/ SSC and 0.1% SDS.
2.4. AM measurement
Peptides were extracted from the conditioned media
using reverse-phase Sep-Pak C-18 cartridges (Waters,
Milford, MA, USA) as previously reported (Lewis et al.,
1998; Martinez et al., 1999). Briefly, 1 ml of conditioned
media was mixed with an equal volume of PBS contain-
ing 0.1% alkali-treated casein and 0.1% Triton X-100,
pH 7.4. Cartridges were activated with 80% methanol
and washed with 0.9% NaCl. Samples were applied to
the columns and, after washing twice with 0.9% NaCl,
AM was eluted with 80% isopropanol containing 125
mM HCl. Extracts were freeze-dried to remove the
organic solvent. The concentration of both hAM and
rAM was measured by RIA analysis, as previously
described (Lewis et al., 1998). In brief, extracts were
reconstituted in 0.4 ml of RIA buffer (10 mM phos-
phate, 50 mM EDTA, 135 mM NaCl, 5 mM NaHCO3,
0.05% Triton X-100, 0.1% Tween-20, 0.1% alkali-treated
casein, pH 7.4). A volume of 0.1 ml of sample or
standard AM (Phoenix Pharmaceuticals, Mountain
View, CA) was preincubated for 18 h at 4 8C with 0.1
ml of primary antibody. After that, 0.1 ml of 125I-AM
(Phoenix Pharmaceuticals, Mountain View, CA) was
added (10,000 cpm) and the mixture was incubated at
4 8C for 18 h. Bound tracer was separated by poly-
ethylene glycol-facilitated precipitation with goat anti -
rabbit serum and normal rabbit serum. The supernatant
was aspirated and the radioactivity in the pellet deter-
mined by a gamma counter.
2.5. Cell proliferation
Cells at 1/103 per well were plated in triplicates in
24-well culture plates with complete media. After 5 days,
the medium was removed and cells were allowed to
detach in the presence of 0.5 ml of 0.05% trypsin/0.53
mM EDTA (Gibco BRL, Rockville, MD). Trypsin was
neutralized with 2 ml of complete medium. 0.5 ml of the
mixture was added to 9.5 ml of isotonic solution (Isoton
II, Coulter Corp., Hialeah, FL) and cells were counted
using Coulter counter (ZF, Coulter Corp., Hialeah, FL).
2.6. Anchorage independent growth in soft agar
Soft agar experiments were performed in six-well
plates using 1/104 cells/ml per well. The bottom layer
contained 2 ml of 0.6% Noble agar (DIFCO, Becton
Dickinson, Sparks, MD), penicillin (100 U/ml), strepto-
mycin (100 mg/ml), 10% FBS and 150 mg/ml hygromycin
B in RPMI 1640 medium. The top layer contained 1 ml
of 0.3% Noble agar, penicillin (100 U/ml), streptomycin
(100 mg/ml), 10% FBS, hygromycin B (150 mg/ml) and
1/104 cells. Parental PC3 cells were cultured in the
same conditions but without hygromycin B. Plates were
incubated for 2 weeks at 37 8C with 5% CO2 to allow
cell proliferation in soft agar. Representative photo-
graphs were taken with a Leica phase contrast micro-
scope. Volumes of the colonies were calculated from the
average radius of randomly selected colonies by image
analysis (analySYS† 3.0 software, Soft Imaging System
GmbH, Munster, Germany).
2.7. Cell cycle analysis
Flow cytometry analysis was performed to examine
the DNA content in each cell cycle phase. Transfectants
and parental PC3 cells were incubated with growth
medium in triplicate T25 flasks for 36 h. After this time,
cells were detached using 0.05% trypsin/0.53 mM
EDTA. One million cells in each sample were treated
with 1 ml of the staining solution containing 50 mg/ml
propidium iodide (Molecular Probes, Inc., Eugene, OR),
0.1% Triton-X, 3.5 mM citrate buffer, 3% polyethylene
glycol and 180 units/ml RNase A (Worthington Bio-
chemical Corp., Lakewood, NY). After 20 min of
incubation at 37 8C, an equal volume of salt solution
was added (50 mg/ml propidium iodide, 0.1% Triton-X,
3.75 M NaCl and 3% polyethylene glycol). Cells were
stored overnight at 4 8C prior to analysis at an
excitation wavelength of 488 nm in a Beckman Coulter
Epics XL-MCL flow cytometer with System II software
(Beckman Coulter, Miami, FL, USA). Cell cycle data
were obtained using Modfit (v5.2) software (Verity
Software House, MN).
2.8. Subcutaneous xenograft tumor in nude mice
Tumorigenicity of AM gene overexpressing sublines
AM17 and AM15 was analyzed in BALB/c strain
athymic nude mice (4-week old males). Mice were
injected subcutaneously with 1/106 cells in 0.2 ml of
complete media. Controls include the empty vector-
transfected Mock2 and parental PC3 cells. Each mouse
was injected in two sites above both forearms. Tumor
sizes were measured every week and volumes were
calculated using the V/(w2/l)/2 formula, as pre-
viously described (Euhus et al., 1986).
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2.9. Statistical analysis
All of the statistical analyses were conducted using the
Student’s t -test (two-tailed). The SPSS 10.0 software
package (SPSS Inc., Chicago, IL) was used to perform
these calculations. Differences were considered statisti-
cally significant if PB/0.05 and very significant if PB/
0.01.
3. Results
3.1. Transfected AM cDNA is expressed in PC3 cells
The rAM cDNA was cloned into pcDNA3.1/Hygro
mammalian expression vector, sequenced and then
transfected into PC3 prostate cancer cells. The cloned
fragment showed a single nucleotide change in its
sequence when compared to other rat preproAM
sequences deposited in GenBank. A cytosine in the
previously described sequences is substituted by a
thymine that leads to alteration in one amino acid
residue in the preproAM sequence (T26I). The substitu-
tion is likely due to polymorphism in the rat preproAM
sequence. The variation is located in the non-conserved
N-terminal region of the PAMP, which is believed to be
non-essential for PAMP function (Mahata et al., 1998).
Human and pig sequences contain a valine instead of a
threonine in that position and thus it is not a well-
conserved amino acid residue.
After selection of stably transfected PC3 sublines, the
expression of the rAM transgene in various sublines was
assessed by Northern blot. Rat AM mRNA expression
was observed only in clones transfected with the rAM
expression vector (Fig. 1). The rAM cDNA probe did
not detect the endogenous hAM mRNA in PC3 parental
or pcDNA3.1 empty vector-transfected cells since the
hybridization was performed with the rat probe at high
stringency conditions. Longer exposure of the film
revealed a faint band corresponding to hAM mRNA
in parental line and empty vector transfected sublines
(data not shown). As shown in Fig. 1, rAM-transfected
clones AM1, AM15 and AM17 expressed considerable
levels of rAM mRNA. The expression level of the rAM
mRNA differs between the three rAM expressing clones.
The AM15 subline showed the highest expression,
followed by AM17. AM1 subline exhibited the lowest
expression among the rAM gene transfected clones.
To determine whether rAM peptide was secreted into
the medium of the transfected sublines, RIA analysis
was carried out using two different antibodies, one for
hAM and another for rAM, to detect the endogenous
and ectopic expression of AM, respectively. Table 1
shows that parental PC3 cells expressed basal levels of
hAM (16.019/1.61 pg/ml/106 cells). Expression of the
AM transgene in AM1, AM15 and AM17 caused a
considerable increase of rAM peptide levels in the
medium with an average of 224.89/25.8 pg/ml/106 cells.
The AM15 clone has the highest secretion of rAM,
followed by AM17 and AM1. No cross-reactivity was
observed between the antibodies against hAM and
rAM. The RIA results are consistent with the Northern
blot results; clones with a higher AM mRNA expression
have also a higher peptide expression.
3.2. AM gene overexpression inhibits PC3 cell
proliferation in culture
The effect of AM gene overexpression on cell
proliferation was tested in a 5-day proliferation assay.
The parental PC3 line, the three rAM transgene expres-
sing clones, and the two empty vector transfected
sublines were used in the assay. Fig. 2 shows that there
was a very significant difference between parental PC3
Fig. 1. Northern blot analysis of AM transgene expression in
transfected PC3 clones. The mRNA derived from the AM transgene
migrates at 1.6 kb position (upper panel ). Ten micrograms of total
RNA was loaded in each line. The methylene blue staining of the total
RNA is indicated (lower panel ).
Table 1
AM peptide levels in conditioned medium
Cell line rAM (pg/ml/106 cells)a hAM (pg/ml/106 cells)b
No cells 0.0309/0.128 /0.0519/0.064
PC3 0.9919/0.323 16.019/1.61
Mock2 /0.1829/0.351 0.1099/0.05
AM1 141.89/26.79 8.8739/0.24
AM15 325.89/45.07 0.6629/0.032
AM17 206.89/5.515 4.4819/1.701
AM levels were measured with RIA as previously described (Lewis
et al., 1998). Two different antibodies, one specific for rAM and
another for hAM, were used in order to discriminate between
endogenous and transfected AM expression. Results are shown with
mean9/SEM.
a Using primary antibody against rAM.
b Using primary antibody against hAM.
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cells and sublines with AM overexpression (PB/0.01).
After 5 days of culture, a 75% decrease in the number of
cells was found in clones overexpressing AM, compared
to parental PC3 cells. Clones transfected with the empty
vector showed a small reduction in growth rates (PB/
0.05), which may reflect clonal variations. However,
growth inhibition due to AM overexpression was much
more dramatic than that caused by the transfection of
the empty vector. These results indicate that AM
overexpression significantly inhibits anchorage-depen-
dent growth of PC3 cells.
To further investigate the impact of the AM gene
overexpression on PC3 cells, we tested the effect of AM
gene overexpression on anchorage-independent growth
in soft agar. Fig. 3A shows that PC3 cells transfected
with AM gene developed significantly fewer colonies
than parental cells or empty vector-transfected cells.
Thus, AM transfection caused a reduction in the
number of colonies growing in soft agar. The pictures
also showed that PC3 cells with AM gene overexpres-
sion developed smaller colonies than controls. In order
to quantify the colony sizes, randomly taken pictures
were studied by image analysis, as described in Section 2
(Fig. 3B). There was no statistically significant differ-
ence between the parental PC3 and mock-transfected
colony sizes (P/0.05), while AM expressing clones
were significantly smaller than control clones (PB/ 0.01).
Parental PC3 colonies had an average volume of 72.329/
14.78 mm3, while the average of AM-expressing clones
(AM1, AM15 and AM17) was 6.4539/0.820 mm3.
Moreover, as observed in the anchorage-dependent
proliferation assays, the extent of colony growth inhibi-
tion was higher for AM15 and AM17 clones than for
AM1 (PB/ 0.01). These results indicate that AM over-
expression caused a very significant reduction of colony
sizes growing in soft agar and that there is an inverse
correlation between expression level of rAM gene and
the size of these colonies (size of the colonies: AM15B/
AM17B/AM1; expression of rAM gene: AM15/
AM17/AM1).
3.3. AM gene overexpression induces G0/G1 cell cycle
arrest in PC3 cells
To determine whether AM overexpression inhibits
proliferation via cell cycle arrest, we conducted a flow
cytometry analysis of parental, empty vector- and the
AM-transfected PC3 cells. The results (Fig. 4) showed
that approximately 66% of the AM-transfected cells
were in the G0/G1 phase, whereas only about 50% of the
parental PC3 and empty-vector transfected cells were in
the G0/G1 phase. This difference was statistically very
significant (PB/0.01). There was no statistical difference
in cell cycle progression between parental PC3 cells and
empty vector transfected cells (P/0.05). As a result of
G0/G1 arrest, AM gene overexpression also caused a
decrease in the percentage of cells in S and G2/M phases.
These results indicate that overexpression of the AM
gene induces G0/G1 growth arrest in PC3 cells.
3.4. AM gene overexpression inhibits PC3 xenograft
tumor growth
The fact that the AM-transfected cells grew less
aggressively in soft agar suggested that these cells might
also have reduced ability to form tumors in nude mice.
To test whether AM gene overexpression inhibits
prostate tumor growth in vivo, subcutaneous xenograft
tumors were generated using AM15 and AM17 sublines,
Mock2, and parental PC3 cells. As shown in Fig. 5, the
growth rates of AM15 and AM17 xenograft tumors
were much slower than those of Mock2 and parental
PC3 xenografts in nude mice. The size of tumors of
empty vector transfected and parental PC3 cells after 5
weeks were similar (780 mm3 approximately). In con-
trast, the size of tumors for clones AM15 and AM17
tumors was much smaller (around 200 mm3). Thus, AM
gene overexpression also inhibited PC3 cell growth in
vivo, as demonstrated by a reduction in the tumor
volume and growth rate.
4. Discussion
AM is a pluripotent peptide hormone expressed in
many tissues and cell lines. AM gene was recently shown
to express abundantly in the rat ventral prostate,
suggesting that AM may play an important role in the
prostate (Pewitt et al., 1999; Wang et al., 1997). The
potential significance of AM gene in the prostate was
further substantiated by detecting AM gene products,
AM and PAMP, in normal human and rat prostate
(Jime´nez et al., 1999). The present study showed for the
first time that overexpression of the rAM gene inhibited
Fig. 2. The effect of AM gene overexpression on PC3 cell proliferation
assay in culture dishes. Cells were plated at 1/103 cells/well and
allowed to grow 5 days before counting. Data shown here are from a
representative experiment repeated three times with similar results.
Bars denote SEM.
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significantly the anchorage-dependent and -independent
growth as well as in vivo tumor growth in the PC3
prostate cancer cell model. Our observations strongly
suggest an involvement of the AM gene in the regulation
of prostate growth and prostate cancer progression.
We have stably transfected PC3 cells with the rAM
cDNA expression vector and isolated three AM over-
expressing clones for characterization in this study. The
expression of transfected rAM cDNA was characterized
by Northern blot and RIA analysis. Northern blot
showed rAM mRNA overexpression in the three clones,
while RIA detected rAM peptide secretion in the
cultured media. The levels of rAM mRNA in stably-
transfected PC3 sublines correlated with the amount of
rAM secreted in culture media. Transfection of rAM
instead of hAM allowed us to discriminate endogenous
from ectopic AM expression. Using the antibody against
hAM, RIA assay demonstrated that parental PC3 cells
secreted a small amount of endogenous AM peptide into
the culture medium (16.019/1.61 pg/ml/106 cells). The
endogenous AM expression level we observed is similar
to those previously described for PC3 cells (Rocchi et
al., 2001) and other cancer cell lines (Nakayama et al.,
1998; Takahashi et al., 1998). In our experiment, AM
gene transfection led to a marked increase in the amount
of AM peptide secreted to the medium, as determined by
RIA using antibodies specific for rAM. Rat AM has
been previously described to bind functional hAM
Fig. 3. The effect of AM gene overexpression on anchorage-independent growth of PC3 cells in soft agar. Cells (1/104) were seeded in 0.3% top
agarose on 0.6% base agar as described in Section 2. (A) Photographs of the colonies were taken after 2 weeks of growth with 4/ objective lens on a
phase contrast microscope. (B) Average volumes of the colonies were calculated using the formula V/3/4pr3 based on the diameters obtained by
digital analysis (analySYS† 3.0 software). Bars denote SEM.
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receptor complexes with an IC50 of 0.75 nM (McLatchie
et al., 1998). The conditioned media of the AM gene
transfected clones contained an average of 0.9599/0.113
nM (224.89/25.79 pg/ml/106 cells) of rAM peptide. The
reported binding affinity for 125I-AM to its receptors
varies from 0.17 to 13 nM (Hinson et al., 2000)
depending on the cell types. The levels of secreted AM
in our transfected clones are thus in the range required
for efficient AM receptor activation.
Several receptors have been described for AM. One of
these receptors, L1, was shown to bind selectively to
AM with high affinity and does not interact with CGRP
(Kapas et al., 1995). The other two reported receptors,
RDC1 and calcitonin receptor-like receptor (CRLR),
bind to AM with lower affinities relative to L1, and
interact with the related peptide CGRP with higher
affinities (Hall et al., 1995; Kapas and Clark, 1995).
Interestingly, CRLR requires the presence of modulat-
ing factors known as receptor activity modifying pro-
teins (RAMPs) (McLatchie et al., 1998). Although there
are no published studies on AM receptors in the
prostate cancer or in prostate cell lines, we have recently
found the specific AM receptor (L1) by RT-PCR in PC3
cells (data not shown). More studies are needed to
clarify whether other types of AM receptors are also
present in prostate cell lines.
The expression of ectopic AM cDNA significantly
inhibited the proliferation of transfected clones in vitro.
A positive correlation was observed between rAM
expression levels and the extent of growth inhibition
among different clones under both anchorage-depen-
dent and -independent conditions. Furthermore, the
inhibitory effect of AM overexpression in PC3 cells
was also observed in vivo, since mice injected with
AM15 and AM17 cells developed very small tumors
relative to the controls. These observations argue that
the AM gene has the potential to play an important role
in growth control of the normal and cancerous prostate.
The mechanism by which AM gene overexpression
inhibits the growth of prostate cancer cells could be
complex. We have tried an in vitro dose-response study
using commercially available AM peptide with PC3
cells. We have repeated the experiments several times
and no significant inhibitory effect was observed (data
not shown). Two possible explanations exist. First, the
half-life of AM peptide is short, about 30 min (Hinson et
al., 2000). Dramatic growth inhibition may require
continuous presence of AM, which can be achieved
conveniently by ectopic expression of the AM gene but
not by treating cells with AM peptide. Second, AM gene
encodes preproAM, which can be processed to generate
several small peptides including AM, PAMP,
proAM4592, and adrenotensin (Kitamura et al.,
1993b, 1994b; Gumusel et al., 1995, 1996). It is possible
that AM, PAMP, proAM4592, and/or adrenotensin
may work together to inhibit cell growth. Mutagenesis
studies will be needed to determine the region in the
preproAM critical for the growth inhibition.
Growth related functions of AM and PAMP peptides
are mainly associated with intracellular cAMP elevation
after AM/PAMP ligand/receptor interaction. PC3 is a
hormone-refractory human prostate carcinoma line that
is markedly growth inhibited by cAMP (Bang et al.,
1992). Thus, cAMP elevation could be involved in the
growth inhibition of PC3 cells by AM gene overexpres-
sion. Further research addressing the signaling pathways
involved in this growth inhibition will be crucial for
understanding the mechanism of AM gene action.
The growth inhibition by the AM gene overexpression
in PC3 cells is due, at least in part, to the G0/G1 cell cycle
arrest. The AM gene overexpression increases the
percentage of cells in the G0/G1 phase and reduces the
Fig. 4. Effect of AM gene overexpression on PC3 cell cycle assayed by
flow cytometry. Triplicate flasks of each cell subline were grown 36 h
under the same conditions and harvested before reaching confluence.
One million cells were stained with propidium iodide (50 mg/ml)
overnight at 4 8C prior to flow cytometry analysis. Data shown are
mean cell percentage values of one single experiment calculated using
Modifit computer software. Similar results were obtained in two other
independent experiments. Bars denote SEM.
Fig. 5. Effect of AM gene overexpression on PC3 xenograft tumor
growth in nude mice. Parental PC3, Mock2, AM15, and AM17 cells
(1/106) were injected subcutaneously behind the forearms. Tumor
volume (mm3) was estimated by the formula described in Section 2.
Data shows the mean9/SEM in duplicate results.
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percentage of the cells in S/G2/M phases, reflecting the
inhibition of the cells to undergo mitosis. It is well
known that prostate cancer progresses from a well-
differentiated stage to a poorly-differentiated state. This
progression is accompanied with a shift in the distribu-
tion of cells from the G0/G1 phase towards the S and G2/
M phases (Neill et al., 1989). AM transgene over-
expression in PC3 cells reversed this shift towards G0/
G1, suggesting that the effect of AM in prostate cancer
may be mediated through cell cycle control.
The growth alterations caused by AM may vary
depending on the genetic background of the receptive
cell. AM stimulates growth in osteoblasts (Cornish et
al., 1997), oral keratinocytes (Kapas et al., 1997),
adrenal cells (Andreis et al., 2000), retinal pigment
epithelial cells (Udono et al., 2000) and teratocarcinoma
cells (Moody et al., 2000), and suppresses growth in
cardiac fibroblasts (Tsuruda et al., 1999), mesangial
(Chini et al., 1995) and neuroblastoma (Ando et al.,
1997) cells. Interestingly, both proliferative (Iwasaki et
al., 1998) and antiproliferative (Kano et al., 1996)
actions have been reported for AM in smooth muscle
cells, depending on the culture conditions.
The inhibition of prostate cancer cell growth by AM
gene overexpression may not be limited to PC3 cell line.
We have tried twice to stably transfect LNCaP human
prostate cancer cells with the same rAM expression
vector. However, we were unable to establish LNCaP
sublines with AM gene overexpression. This observation
suggests that rAM overexpression is detrimental to
LNCaP cells.
In summary, this study showed that AM gene over-
expression significantly inhibited the growth of the PC3
human prostate cancer cell line in vivo and in vitro,
possibly through the G0/G1 checkpoint. Elucidating the
mechanism of AM gene inhibition of prostate cancer
growth may lead to novel approaches for prostate
cancer treatment.
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